Last checked at 
LONDON (Alliance News) - Allergy vaccines developer Allergy Therapeutics PLC on Friday noted a study published in the Immunotherapy journal on its Acarovac Plus house dust mite treatment.
Allergy Therapeutics said a statistically significant reduction in symptom scores was seen in the follow-up visits conducted by Dr Albert Roger, director of the Allergy Unit at Universitari Hospital Trias I Pujol, Badalona, Spain.
After one year, the follow-up tests showed a reduction in symptoms in excess of 50%, with significant improvements in immunological markers also noted.
Allergy said Acarovac sales in Spain and Portugal have increased in 2016, and it anticipates further growth in dust mite treatment sales in Europe in coming years.
"This data further reinforces the benefits of Acarovac Plus in the perennial allergy vaccine market," said Manuel Llobet, chief executive of Allergy Therapeutics.
Shares in the firm were untraded on Friday morning, having last traded at 18.75 pence.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
